InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Taysha Gene Therapies, Inc.

TSHA Clue Score55
United States Fiscal year ends December CIK 0001806310
$4.49 +1.35% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $4.49 −75.60% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 24 Sep 2020. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2020Operating income−43.0Net income−60.0Fiscal year 2021Operating income−173.3Net income−174.5EPS, diluted−4.64Fiscal year 2022Revenue2.5Operating income−162.4Net income−166.0EPS, diluted−3.78Fiscal year 2023Revenue15.5 +517.5%Operating income−72.4Net income−111.6EPS, diluted−0.96Fiscal year 2024Revenue8.3 −46.1%Operating income−91.5Net income−89.3EPS, diluted−0.36Fiscal year 2025Revenue9.8 +17.3%Operating income−110.5Net income−109.0EPS, diluted−0.34
FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a 2.5 15.5 8.3 9.8
Growth +517.5% −46.1% +17.3%
Operating income −43.0 −173.3 −162.4 −72.4 −91.5 −110.5
Net income −60.0 −174.5 −166.0 −111.6 −89.3 −109.0
Growth
EPS, diluted n/a −4.64 −3.78 −0.96 −0.36 −0.34

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2020Fiscal year 2021Fiscal year 2022Operating margin−6,492.7%Net margin−6,635.3%Free cash flow margin−4,356.9%Fiscal year 2023Operating margin−468.8%Net margin−722.1%Free cash flow margin−497.6%Fiscal year 2024Operating margin−1,097.6%Net margin−1,071.6%Free cash flow margin−979.2%Fiscal year 2025Operating margin−1,130.6%Net margin−1,115.3%Free cash flow margin−960.1%
FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a −6,492.7% −468.8% −1,097.6% −1,130.6%
Net margin n/a n/a −6,635.3% −722.1% −1,071.6% −1,115.3%
Free cash flow margin n/a n/a −4,356.9% −497.6% −979.2% −960.1%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−30.7Capital expenditure−0.1Free cash flow−30.8Fiscal year 2021Operating cash flow−117.0Capital expenditure−15.3Free cash flow−132.3Fiscal year 2022Operating cash flow−88.4Capital expenditure−20.6Free cash flow−109.0Fiscal year 2023Operating cash flow−73.0Capital expenditure−3.9Free cash flow−76.9Fiscal year 2024Operating cash flow−81.2Capital expenditure−0.4Free cash flow−81.6Fiscal year 2025Operating cash flow−93.1Capital expenditure−0.7Free cash flow−93.8
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −30.7 −117.0 −88.4 −73.0 −81.2 −93.1
Capital expenditure −0.1 −15.3 −20.6 −3.9 −0.4 −0.7
Free cash flow −30.8 −132.3 −109.0 −76.9 −81.6 −93.8
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2020Cash251.3Shareholders’ equity251.3Fiscal year 2021Cash149.1Total debt37.2Net cash (debt)111.9Shareholders’ equity95.4Debt to equity0.39Fiscal year 2022Cash87.9Total debt38.0Net cash (debt)49.9Shareholders’ equity0.9Debt to equity40.01Fiscal year 2023Cash143.9Total debt40.5Net cash (debt)103.4Shareholders’ equity74.9Debt to equity0.54Fiscal year 2024Cash139.0Total debt43.9Net cash (debt)95.1Shareholders’ equity71.5Debt to equity0.61Fiscal year 2025Cash319.8Total debt50.1Net cash (debt)269.7Shareholders’ equity246.9Debt to equity0.20
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 251.3 149.1 87.9 143.9 139.0 319.8
Total debt n/a 37.2 38.0 40.5 43.9 50.1
Net cash (debt) n/a 111.9 49.9 103.4 95.1 269.7
Shareholders’ equity 251.3 95.4 0.9 74.9 71.5 246.9
Debt to equity n/a 0.39 40.01 0.54 0.61 0.20

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023† 31 Dec 2023 FY2024† 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
n/a n/a 2.5 15.5 8.3 9.8
Growth +517.5% −46.1% +17.3%
31.9 131.9 91.2 56.8 66.0 86.4
11.1 41.3 37.4 30.0 29.0 33.9
−43.0 −173.3 −162.4 −72.4 −91.5 −110.5
Growth
0.0 n/a 0.0 0.0 0.0 0.0
−60.0 −174.5 −166.0 −111.6 −89.3 −109.0
Growth
Per share
n/a −4.64 −3.78 −0.96 −0.36 −0.34
n/a −4.64 −3.78 −0.96 −0.36 −0.34
Growth
n/a 37.7 44.0 116.1 250.1 319.7
n/a 37.7 44.0 116.1 250.1 319.7
Growth +16.7% +164.2% +115.4% +27.8%

† The diluted share count jumps at 2023 and 2024, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 6 of 6 years on file.